Business Wire

Galderma to Unveil Ground-breaking Data From Across Its Leading Dermatology Portfolio and Showcase Major Update for Sensitive Skincare Brand CETAPHIL® at the 2021 EADV Congress

Share

Galderma’s presence at the 2021 European Academy of Dermatology and Venereology (EADV) virtual congress on September 29 – October 2 will reveal new data and showcase the company’s sophisticated portfolio and services across the spectrum of dermatology. The company’s redesigned virtual booth will have dedicated areas presenting Galderma’s innovations in Consumer Care and Prescription Medicine.

Unveiling new data in Prescription Medicine

The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis. Attendees will have the opportunity to ask questions to the faculties during live Q&A sessions.

On Thursday, September 30, Professor Alison Layton^ will chair the symposium Personalizing Acne: Consensus of Experts to Optimize Acne Management. Together with her co-speakers, Professor Layton will provide practical solutions for longitudinal management of acne.

On the same day, Professor Gil Yosipovitch^ will present the symposium Prurigo Nodularis: From Patient to Pathway, which will discuss the multi-dimensional impact of the disease and reveal new clinical data for the investigational drug, nemolizumab*.

The symposium Moderate to Severe Atopic Dermatitis – A Disease in the Skin and Beyond will take place on Friday, October 1. Chaired by Professor Diamant Thaçi, the session will cover the role of neuro-immune cytokine IL-31 in atopic dermatitis and present emerging clinical data on the effect of nemolizumab* in blocking IL-31 signaling in the disease.

In the symposium New insights on Papulopustular Rosacea and Systemic Therapy on October 1, the speakers will discuss the importance of long-term management strategies in rosacea. Dr. James Q. Del Rosso^ will present original data on the impact of 52 weeks’ use of doxycycline 40mg MR on relapse rate in moderate to severe papulopustular rosacea patients.

On Saturday, October 2, Professor Rolf-Markus Szeimies^ and Professor Serge Mordon^ will host the industry hub Artificial Daylight Photodynamic Therapy: Advancing Actinic Keratosis Treatment. They will present the newly approved modality and main approved artificial daylight devices, as well as a demonstration video.

Galderma will also showcase its latest acne treatment, AKLIEF® (trifarotene) Cream, 0.005%, specifically designed for both facial and truncal acne.

Showcasing advanced solutions in Consumer Care

Visitors will be able to explore highlights from the CETAPHIL® portfolio of 61 products and the largest update in the brand’s 70-year history. As part of the update, CETAPHIL’s iconic, best-selling cleansers and moisturizers—Gentle Skin Cleanser, Daily Facial Cleanser, Moisturizing Cream, Moisturizing Lotion, and Advanced Relief Lotion—have been reformulated. With their dermatologist-backed blend of hydrating and skin-nourishing ingredients, including niacinamide, panthenol and hydrating glycerin, the range of products helps improve the overall resilience of sensitive skin.

CETAPHIL’s latest research will be unveiled through two dedicated symposia. On Thursday, September 30, Dr. Krzysztof Piotrowski^ will chair the symposium Pediatric Atopic Dermatitis: Current Developments. Professor Adelaide Hebert^ will focus on the latest updates in the field of pediatric atopic dermatitis while Dr. Mark Koh^ will then present his findings and answer the question, “Is it possible to prevent atopic dermatitis from birth?”.

On Friday, October 1, Professor Giovanni Pellacani^ will chair the symposium Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology. Key speakers Professor Laurent Misery^ and Dr. Emilie Brenaut^ will present their latest research findings and focus on what sensitive skin is, how it can be distinguished from non-sensitive skin and methods for profiling.

Experts from BENZAC® and LOCERYL® will present new findings relating to maskne and onychomycosis through two industry hubs: on Thursday, September 30, Dr. Markus Reinholz^ will chair The Many Faces of Maskne – a New Skin Burden / an Upcoming Disease, featuring speaker Dr. Anne-Charlotte Kuna^. On Friday, October 1, Dr. Dieter Reinel^ will host Onychomycosis Update – Novel Findings: Prevalence, Epidemiology and Topical Therapy.

* Nemolizumab is an investigational drug not approved for any indication in any jurisdiction.

^All speakers are paid consultants of Galderma.

 

“Galderma is a proud partner of the EADV Congress and we are thrilled to be showcasing our latest innovations and data across our dermatology portfolio. As a company, we are fully committed to advancing dermatology for every skin story.”

 

BALDO SFORZOLINI, Ph.D.

GLOBAL HEAD OF R&D, GALDERMA

 

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information:

About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.10 While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.11
The global prevalence of PN is unknown as there are no studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000. In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.12

About nemolizumab
Nemolizumab is a first-in-class humanized monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.6 IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus (itching). With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is the bridge between the immune and nervous systems while directly acting on structural cells in the skin. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority. Nemolizumab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis.

About AKLIEF
In the European Union, AKLIEF® (trifarotene 50 mcg/g cream) is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. It is the only topical retinoid that specifically targets retinoic acid receptor gamma (RAR-γ), the most common RAR in the skin.13, 14 National marketing authorizations across concerned European member states will follow in 2020.

About CETAPHIL
CETAPHIL was developed by a leading pharmacist more than 70 years ago as a gentle, yet powerful formula to clean without stripping and moisturize without clogging. CETAPHIL is the #1 dermatologist-recommended brand in Germany and the #1 doctor-recommended sensitive skincare brand in the U.S. and is now available in Switzerland. New additions to the brand are regularly developed with the help of leading global skincare experts, providing innovative skincare technologies for sensitive skin that help restore, protect, and maintain skin health every day. For more information, visit www.cetaphil.com.

About BENZAC
BENZAC is an acne brand proposing treatments based on Benzoyl Peroxide active ingredient, as well as acne specific regimen companion products (including cleansers and moisturizers).

About LOCERYL
LOCERYL is the number one nail antifungal brand globally.16 Its treatment is based on amorolfine active ingredient.

-----------------

1. Tan J, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):551–6.

2. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013;168:474–85.

3. Hay RJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527–34.

4. Del Rosso JQ, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007;6:597–600.

5. Layton AM, et al. Reviewing the global burden of acne: how could we improve care to reduce the burden? Br J Dermatol 2021;184:219–225.

6. Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205

7. Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1

8. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl1):8-16. DOI: https://doi.org/10.1159/000370220

9. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021.

10. Galderma. Data on File.

11. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021

12. Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. 2021.

13. Aubert J, et al. Br J Dermatol 2018;179:442–56.

14. Fisher GJ, et al. J Biol Chem 1994;269(32):20629–35.

15. Health Canada. Approval of Aklief. Available at: Register of Innovative Drugs - Canada.ca (last access December 2019)

16. Nicholas Hall’s global CHC database, DB6

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Lauren Starr
Head of Franchise Communications
media@galderma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IPS acquires Linesight and partners for strategic growth18.10.2021 17:00:00 EEST | Press release

IPS-Integrated Project Services, LLC, headquartered in Blue Bell, Pennsylvania and a subsidiary of Alleghany Capital Corporation, today announced that it has acquired Linesight, a multinational consulting firm headquartered in Dublin, Ireland. IPS is a large EPCMV (Engineering, Procurement, Construction Management and Validation) company with over 1,700 staff across 22 offices worldwide. Linesight is a fast-growing professional consultancy services organization providing project controls to data center providers, life sciences companies, commercial real estate, healthcare, hospitality, retail and residential sectors. Linesight has over 900 staff across 24 offices globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005645/en/ The acquisition is being approached as a future integrated partnership where IPS will leverage Linesight’s experience and expertise in particular in the data center sector and Linesight in tur

Sumitomo SHI FW (SFW) Add CADMATIC Solutions to Further Support Digitalization, Data-driven Engineering, and Project Management18.10.2021 16:29:00 EEST | Press release

SFW is a provider of power, energy storage and environmental technologies and services for the global energy industry and has now entered into an agreement with CADMATIC Ltd to implement CADMATIC 3D plant design and information management solutions in their engineering projects in Finland, Poland, India, and China. The goal of the investment is to shorten lead times in design, engineering, and construction, improve the quality of design, and harmonize working methods across its international office network and subcontractors. The design and construction of a power plant is an extremely complex process that requires the integration of multiple design, engineering and construction disciplines, and many suppliers. CADMATIC software is an important element to streamline the process from design and engineering to construction and production and seamlessly integrate multiple parties in one project. Technical advantages in 3D Design, work-sharing, information management, and visualization wer

Deel Raises $425M in Series D Funding to Continue Transforming the Future of Work18.10.2021 15:45:00 EEST | Press release

Deel, the remote hiring company shattering job barriers worldwide, announced today that it has raised $425 million in Series D funding, taking the total amount raised by the company to over $630 million. The latest funding round values the company at $5.5 billion. Deel has become the highest valued company in the global hiring, payments, and compliance space with this investment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005567/en/ Deel Interface (Graphic: Business Wire) This new funding round was led by US-based Coatue, with partners Rahul Kishore and Lucas Swisher leading the deal. Several new and existing investors also participated in this round, including Altimeter Capital, Andreessen Horowitz, the YC Continuity Fund, Spark Capital, Greenbay Ventures, Neo, and over 40 of the world’s leading operators. Since Deel’s inception in 2019, the team - growing from four to 400 employees - has been on a mission to make

William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today18.10.2021 15:30:00 EEST | Press release

Everbridge, Inc. (NASDAQ: EVBG) today announced the launch of its podcast Unlocking Resilience™: Global Leadership Series featuring William Shatner as its inaugural guest. The first-of-its-kind podcast features global influencers, government leaders, C-level executives and top healthcare experts as they discuss the confluence of leadership, technology and resilience at both the personal and organizational level. Topics will include overcoming personal challenges to create a life of resilience; effective strategies for building organizational resilience and business continuity in the face of critical events; and perspectives on the future of work, life and entertainment in a post-pandemic world, among other topics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005565/en/ William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today (Graphic: Business Wire) The Unlocking

Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection and IBD at ACG 202118.10.2021 15:00:00 EEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 – 27, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005060/en/ Eligibility criteria in CDI clinical trials often are narrowly defined, excluding broader patient populations. The first presentation will explore key health outcomes of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI), among patients in a real-world setting. The second analysis evaluates healthcare resource utilization and medical costs among Medicare patients with CDI with or without inflammatory bowel disease (IBD) as a comorbidity. Notably, one of the presentations has received The

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes18.10.2021 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). This is the first demonstration of a patient with T1D achieving robust restoration of islet cell function from such a cell therapy. The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy. The patient achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures, including increases in fasting and stimulated C-peptide, improvements in glycemic control, including HbA1c, and decreases in exogenous insulin requirement. VX-880 was generally well tolerated. “These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were ac

Industrial Flow Solutions™ Announces Deal to Acquire Clearwater Controls™ to Grow IoT Solutions for Wastewater Network Management, Increase Demand for Industry-Leading DERAGGER™+18.10.2021 14:06:00 EEST | Press release

Leading industrial pumping solutions provider Industrial Flow Solutions™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd.™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/ Clearwater Controls' DERAGGER™ products offer intelligent efficiency and the end of ragging. Industrial Flow Solutions has announced a deal to acquire Clearwater Controls to grow IoT solutions for wastewater network management. Clearwater Controls offers a broad line of wastewater solutions, beginning with its lead

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom